PharmEasy parent API Holdings withdraws Rs 6,250 cr DRHP, eyes rights issue
API Holdings has pulled its 2021-filed Rs 6,250 crore IPO papers from SEBI and is weighing a rights issue to existing backers including Prosus, TPG and Temasek. The retreat reflects cooling appetite for new-age listings and follows the Rs 4,546 crore Thyrocare buy that stretched the balance sheet.
API Holdings, parent of online pharmacy PharmEasy, has withdrawn its Rs 6,250 crore DRHP filed with SEBI in 2021 and is weighing a rights issue to existing shareholders to raise capital amid weak market conditions for new-age listings.
Why this matters
PharmEasy parent's IPO retreat marks a major reset after the debt-funded Rs 4,546 cr Thyrocare buyout, shifting funding strategy from public markets to existing PE/sovereign backers.
Retail-company signals steady at 1,224 in last 90 days, reflecting consistent corporate activity.
Also reported by
- Moneycontrol · Results — Same time
- Moneycontrol · Results — Same time